StockData
Axogen, Inc. logo

Axogen, Inc. (AXGN) stock

AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/30142% above fair value
$55.37−0.01 (-0.02%)

Close on Nov 17, 2026Market cap $3.31BP/E –Yield –

Axogen r&d expenses

Research and development expenses are spending on new products and technology.

Axogen's R&D Expenses for the twelve months ending Sep 30, 2026 was $37.43M, up 37.6% year over year. For fiscal 2025 it was $32.89M, up 18.4% from the year before. Over ten years it grew 26.1% a year on average. The highest annual figure on record is $32.89M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.89M+18.4%
FY2024Dec 31, 2024$27.77M+1.6%
FY2023Dec 31, 2023$27.34M+6.7%
FY2022Dec 31, 2022$25.63M+6.0%
FY2021Dec 31, 2021$24.18M+35.5%
FY2020Dec 31, 2020$17.85M+1.9%
FY2019Dec 31, 2019$17.51M+48.8%
FY2018Dec 31, 2018$11.77M+75.7%
FY2017Dec 31, 2017$6.70M+59.0%
FY2016Dec 31, 2016$4.21M+30.1%
FY2015Dec 31, 2015$3.24M+6.7%
FY2014Dec 31, 2014$3.03M+42.7%
FY2013Dec 31, 2013$2.13M+48.9%
FY2012Dec 31, 2012$1.43M+104.7%
FY2011Dec 31, 2011$697.36K+59.9%
FY2010Dec 31, 2010$436.01K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$8.95M+18.3%
Q2 FY2026Jun 30, 2026$8.59M+25.3%
Q1 FY2026Mar 31, 2026$7.52M+23.4%
Q4 FY2025Dec 31, 2025$12.38M+84.6%
Q3 FY2025Sep 30, 2025$7.57M+8.1%
Q2 FY2025Jun 30, 2025$6.85M+2.9%
Q1 FY2025Mar 31, 2025$6.09M-17.8%
Q4 FY2024Dec 31, 2024$6.70M-6.6%
Q3 FY2024Sep 30, 2024$7.00M+4.5%
Q2 FY2024Jun 30, 2024$6.66M-6.8%
Q1 FY2024Mar 31, 2024$7.41M+17.1%
Q4 FY2023Dec 31, 2023$7.18M+35.9%
Q3 FY2023Sep 30, 2023$6.69M-5.0%
Q2 FY2023Jun 30, 2023$7.14M+1.7%
Q1 FY2023Mar 31, 2023$6.33M+0.8%
Q4 FY2022Dec 31, 2022$5.28M-16.2%
Q3 FY2022Sep 30, 2022$7.05M+10.1%
Q2 FY2022Jun 30, 2022$7.02M+22.7%
Q1 FY2022Mar 31, 2022$6.28M+9.2%
Q4 FY2021Dec 31, 2021$6.30M+27.8%
Q3 FY2021Sep 30, 2021$6.40M+51.4%
Q2 FY2021Jun 30, 2021$5.72M+40.6%
Q1 FY2021Mar 31, 2021$5.75M+24.6%
Q4 FY2020Dec 31, 2020$4.93M+0.4%
Q3 FY2020Sep 30, 2020$4.23M+1.2%
Q2 FY2020Jun 30, 2020$4.07M-4.9%
Q1 FY2020Mar 31, 2020$4.61M+11.5%
Q4 FY2019Dec 31, 2019$4.91M+29.1%
Q3 FY2019Sep 30, 2019$4.18M+26.4%
Q2 FY2019Jun 30, 2019$4.28M+64.6%
Q1 FY2019Mar 31, 2019$4.14M+101.1%
Q4 FY2018Dec 31, 2018$3.81M+93.1%
Q3 FY2018Sep 30, 2018$3.31M+84.2%
Q2 FY2018Jun 30, 2018$2.60M+71.0%
Q1 FY2018Mar 31, 2018$2.06M+45.8%
Q4 FY2017Dec 31, 2017$1.97M+67.3%
Q3 FY2017Sep 30, 2017$1.80M–
Q2 FY2017Jun 30, 2017$1.52M–
Q1 FY2017Mar 31, 2017$1.41M–
Q4 FY2016Dec 31, 2016$1.18M–

More Axogen figures

See a number that looks wrong?